The net loss applicable to common stockholders for the first nine months of 2010 was $132.3 million, or $1.17 per share based on 113.2 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $160.6 million, or $1.54 per share based on 104.4 million weighted average shares outstanding, for the first nine months of 2009.

Cash, cash equivalents and marketable securities were $98.0 million at September 30, 2010 and $32.5 million at December 31, 2009. As of September 30, 2010, the Company had $98.0 million of available borrowings under the loan agreement with The Mann Group, an entity controlled by the Company's principal stockholder. In August 2010, the Company sold $100.0 million of convertible notes in a Rule 144A offering. The net proceeds to the Company from the offering after expenses were $95.8 million.

"During this past quarter we were primarily focusing on preparations for commercial readiness and for an AFREZZA partnership," said Alfred Mann, Chairman and Chief Executive Officer. "In addition, we executed a multi-part strategy in which we added close to $100 million from an offering of convertible notes and put in place a series of equity sales intended to raise additional funds over the next year, provided our stock price exceeds the floor price that we set. Finally, paralleling that transaction we also established a mechanism, which is now being executed, to retire a portion of the debt under The Mann Group loan agreement."

Source: MannKind Corporation

Tag Cloud

Buy Atopex Without Prescription
Buy Drontal Allwormer For Cats Without Prescription
Buy Heartgard Chewable Without Prescription
Buy Heartz (Medium Dogs) Without Prescription
Buy Heartz (Small Dogs) Without Prescription
Buy Opticare Ointment Without Prescription
Buy Otibact Without Prescription
Buy Otikfree Ear Drops Without Prescription
Buy Petcam (Metacam) Oral Suspension Without Prescription
Buy Pyrantel Pamoate Suspension Without Prescription
Buy Seledruff Shampoo Without Prescription